Healthcare
Data show that the implantation procedure of the Genio® system is relatively non-invasive
SkinBioTherapeutics has announced its full year results and released details of its strengthened board and management team following the appointment of Stuart Ashman CEO.
Researchers found that the treatment delayed the development of ALS symptoms in the mice with the ALS mutations.
BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session
Surface Oncology announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations
Harpoon Therapeutics, Inc. announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference.
INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development.
On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.
Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.
PRESS RELEASES